Hepatocellular carcinoma in Asia: Prevention strategy and planning

World Journal of Hepatology

Volumn 7, Issue 12, 2015, Pages 1708-1717

  Ashtari, Sara ^a   Pourhoseingholi, Mohamad Amin ^a   Sharifian, Afsaneh ^a   Zali, Mohamad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Asian countries; Hepatocellular carcinoma; Prevention strategy; Viral hepatitis

Indexed keywords

EID: 84934285202     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i12.1708     Document Type: Review

References (127)

1. IARC. Liver Cancer: Estimated Incidence, Mortality, Prevalence Worldwide in 2012. [Accessed 2013 Dec 12]. Available from: URL: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx2012.
2. Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014; 8: 71-76 [PMID: 24899827 DOI: 10.4137/CMO. S9926].
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210].
4. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458 [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100].
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107].
6. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-353 [PMID: 19220670 DOI: 10.1111/j.1440-1746.2009.05784.x].
7. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74].
8. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3: S206-S214 [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5].
9. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. Lyon: IARC Press, 2001.
10. Poustchi H, Sepanlou S, Esmaili S, Mehrabi N, Ansarymoghadam A. Hepatocellular carcinoma in the world and the middle East. Middle East J Dig Dis 2010; 2: 31-41 [PMID: 25197510].
11. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290-296 [PMID: 11668511].
12. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 Suppl 4: 5-13 [PMID: 21115576 DOI: 10.1634/theoncologist.2010-S4-05].
13. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j. gastro.2007.04.061].
14. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124 [PMID: 17615358 DOI: 10.1126/science.1140485].
15. Nagasue N, Ogawa Y, Yukaya H, Ohta N, Ito A. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology 1985; 88: 768-772 [PMID: 2981753].
16. Cancer incidence in five continents. Volume VIII. IARC Sci Publ 2002; (155): 1-781 [PMID: 12812229].
17. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-2094 [PMID: 14697813 DOI: 10.1016/S0140-67 36(03)15108-2].
18. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v [PMID: 15831268 DOI: 10.1016/j.cld.2004.12.009].
19. Salim EI, Moore MA, Al-Lawati JA, Al-Sayyad J, Bazawir A, Bener A, Corbex M, El-Saghir N, Habib OS, Maziak W, Mokhtar HC, Seif-Eldrin IA, Sobue T. Cancer epidemiology and control in the arab world-past, present and future. Asian Pac J Cancer Prev 2009; 10: 3-16 [PMID: 19469617].
20. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44 Suppl 19: 102-107 [PMID: 19148802 DOI: 10.1007/s00535-008-2251-0].
21. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1652-1656 [PMID: 18350595 DOI: 10.3748/wjg.14.1652].
22. Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009; 286: 5-8 [PMID: 19070421 DOI: 10.1016/j.canlet.2008.10.046].
23. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300].
24. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683].
25. Kim do Y, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2-14 [PMID: 24159567 DOI: 10.1159/000339016].
26. Parikh A, Taouli B. Imaging of hepatocellular carcinoma: current concepts. Recent Results Cancer Res 2013; 190: 33-55 [PMID: 22941012 DOI: 10.1007/978-3-642-16037-0_3].
27. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1].
28. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963: 13-20 [PMID: 12095924 DOI: 10.1111/j.1749-6632.2002.tb04090.x].
29. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006; 25: 3771-3777 [PMID: 16799618 DOI: 10.1038/sj.onc.1209560].
30. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37 Suppl 2: S88-S94 [PMID: 17877502 DOI: 10.1111/j.1872-034X.2007.00168.x].
31. Simonetti RG, Cammà C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972 [PMID: 1649041 DOI: 10.1007/BF01297149].
32. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-154 [PMID: 15918143 DOI: 10.1055/s-2005-871194].
33. World Health Organization. Global Alert and Response (GAR): Hepatitis B. Available from: URL: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html.
34. Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon 2012; 12: e6894 [PMID: 23233864 DOI: 10.5812/hepatmon.6894].
35. Smolle E, Zöhrer E, Bettermann K, Haybaeck J. Viral hepatitis induces hepatocellular cancer: what can we learn from epidemiology comparing iran and worldwide findings? Hepat Mon 2012; 12: e7879 [PMID: 23233866 DOI: 10.5812/hepatmon.7879].
36. Qirbi N, Hall AJ. Epidemiology of hepatitis B virus infection in the Middle East. East Mediterr Health J 2001; 7: 1034-1045 [PMID: 15332746].
37. André F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000; 18 Suppl 1: S20-S22 [PMID: 10683538 DOI: 10.1016/S0264-410X(99)00456-9].
38. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006; 119: 1946-1952 [PMID: 16708389 DOI: 10.1002/ijc.22045].
39. Chen CH, Su WW, Yang SS, Chang TT, Cheng KS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. J Gastroenterol Hepatol 2006; 21: 1561-1566 [PMID: 16928217 DOI: 10.1111/j.1440-1746.2006.04425.x].
40. Al-Faleh FZ, Ayoola EA, Al-Jeffry M, Arif M, Al-Rashed RS, Ramia S. Integration of hepatitis B vaccine into the expanded program on immunization: The Saudi Arabian experience. Ann Saudi Med 1993; 13: 231-236 [PMID: 17590667].
41. Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 2005; 194: 163-168 [PMID: 15834754 DOI: 10.1007/s00430-004-0231-4].
42. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM. Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev 2010; 11: 859-862 [PMID: 21133591].
43. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J 2005; 26: 974-977 [PMID: 15983686].
44. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007; 16: 403-406 [PMID: 18193122].
45. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci 2009; 14: 249-258 [PMID: 21772891].
46. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143 [PMID: 18695135 DOI: 10.1093/jnci/djn243].
47. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-1006 [PMID: 2572739 DOI: 10.1016/S0140-6736(89)91015-5].
48. Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 1995; 25: 27-32 [PMID: 8875606].
49. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472 [PMID: 9024300 DOI: 10.1053/gast.1997.v112.pm9024300].
50. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008; 28: 175-188 [PMID: 18251977 DOI: 10.1111/j.1478-3231.2007.01652.x].
51. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331 [PMID: 11836196 DOI: 10.1093/aje/155.4.323].
52. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, Coppola RC, Sauleda S, Thursz MR, Tillmann H, Alberti A, Braconier JH, Esteban JI, Hadziyannis SJ, Manns MP, Saracco G, Thomas HC, Trépo C. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol 2000; 12: 667-678 [PMID: 10912488 DOI: 10.1097/00042737-200012060-0 0017].
53. World Health Organization. Global database on blood safety summary report: 1998-1999. Available from: URL: http://www. who.int/bloodsafety/global_database/en/.
54. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, Kako M, Ujiie N, Endo C, Matsui A. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744-750 [PMID: 8107740 DOI: 10.1056/NEJM19940317330 1103].
55. Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fararouei M. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med 2012; 15: 271-274 [PMID: 22519374].
56. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567 [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4].
57. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 41-46 [PMID: 16614741 DOI: 10.7150/ijms.3.41].
58. Miyakawa Y, Iino S. Toward prevention of hepatocellular carcinoma developing in chronic hepatitis C. J Gastroenterol Hepatol 2001; 16: 711-714 [PMID: 11446875 DOI: 10.1046/j.1440-1746.2001.02543.x].
59. Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK, Selim OE, Badran HM. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. Hepatol Res 2001; 19: 170-179 [PMID: 11164741].
60. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 Suppl 2: 61-80 [PMID: 21651703 DOI: 10.1111/j.1478-3231.2011.02540.x].
61. Fakeeh M, Zaki AM. Hepatitis C: prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia. Am J Trop Med Hyg 1999; 61: 889-892 [PMID: 10674665].
62. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, Zaer-rezaii H, Amini-Kafiabad S, Maghsudlu M, Pourshams A, Malekzadeh R, Esmaili S. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 2010; 14 Suppl 3: e113-e116 [PMID: 20362479 DOI: 10.1016/j.ijid.2009.11.032].
63. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521, 521.e1-6 [PMID: 19861128 DOI: 10.1053/j.gastro.2009.09.067].
64. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423].
65. Møller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A: 344-350 [PMID: 8204357 DOI: 10.1016/0959-8049(94)9025 4-2].
66. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101 DOI: 10.1053/j. gastro.2004.09.014].
67. Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127: S56-S61 [PMID: 15508104 DOI: 10.1053/j.gastro.2004.09.016].
68. Amit S, Jorge A M. Screening for hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2008; 4: 201-208 [PMID: 21904498].
69. Miller JC, Hahn PF, Chung RT, Thrall JH, Lee SI. Screening for hepatocellular carcinoma in cirrhotic patients. J Am Coll Radiol 2008; 5: 1012-1014 [PMID: 18755444 DOI: 10.1016/j. jacr.2008.01.017].
70. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 2001; 36: 651-660 [PMID: 11686474 DOI: 10.1007/s005350170027].
71. Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc 2007; 70: 141-145 [PMID: 17475593 DOI: 10.1016/S1726-4901(09) 70346-6].
72. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol 2014; 26: 78-88 [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004].
73. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645].
74. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virusinduced hepatocarcinogenesis. J Hepatol 2009; 51: 810-820 [PMID: 19545926 DOI: 10.1016/j.jhep.2009.05.008].
75. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003].
76. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 2009; 4: 399-415 [PMID: 18928409 DOI: 10.1146/annurev. pathol.4.110807.092202].
77. Koike K. Pathogenesis of HCV-associated HCC: Dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res 2007; 37 Suppl 2: S115-S120 [PMID: 17877471 DOI: 10.1111/j.1872-034X.2007.00173.x].
78. Bartosch B. Hepatitis B and C viruses and hepatocellular carcinoma. Viruses 2010; 2: 1504-1509 [PMID: 21994691 DOI: 10.3390/v2081504].
79. Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol 2006; 23: 47-63 [PMID: 21326720 DOI: 10.1055/s-2006-939841].
80. Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 2009; 286: 22-28 [PMID: 19345001 DOI: 10.1016/j.canlet.2009.02.053].
81. IARC. Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. Lyon: IARC Press, 1993.
82. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3-10 [PMID: 8118382].
83. Wu W. Occupational cancer epidemiology in the People's Republic of China. J Occup Med 1988; 30: 968-974 [PMID: 3068337 DOI: 10.1097/00043764-198812000-00017].
84. Wang JS, Huang T, Su J, Liang F, Wei Z, Liang Y, Luo H, Kuang SY, Qian GS, Sun G, He X, Kensler TW, Groopman JD. Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2001; 10: 143-146 [PMID: 11219772].
85. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, Wu MH, Wu WP, Wang LW, Wang Q, Huang GT, Yang PM, Lee HS, Santella RM. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67: 620-625 [PMID: 8782648 DOI: 10.1002/(SICI)1097-0215(19960904)67:5<620:: AID-IJC5>3.0.CO;2-W].
86. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2009; 18: 846-853 [PMID: 19273485 DOI: 10.1158/1055-9965.epi-08-0697].
87. Chen CH, Wang MH, Wang JH, Hung CH, Hu TH, Lee SC, Tung HD, Lee CM, Changchien CS, Chen PF, Hsu MC, Lu SN. Aflatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus endemic area in Taiwan. Am J Trop Med Hyg 2007; 77: 747-752 [PMID: 17978082].
88. Abdel-Hamid NM. Recent insights on risk factors of hepatocellular carcinoma. World J Hepatol 2009; 1: 3-7 [PMID: 21160959 DOI: 10.4254/wjh.v1.i1.3].
89. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213 [PMID: 12395331 DOI: 10.1053/jhep.2002.36780].
90. Braga C, La Vecchia C, Negri E, Franceschi S. Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer 1997; 33: 629-634 [PMID: 9274446 DOI: 10.1016/S0959-8049(96)00500-X].
91. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, Gelatti U, Portera G, Boffetta P, Nardi G. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a casecontrol study in Italy. Brescia HCC Study. Hepatology 1997; 26: 579-584 [PMID: 9303486 DOI: 10.1002/hep.510260308].
92. Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012; 156: 841-847, W295 [PMID: 22711076 DOI: 10.7326/0003-4819-156-1 2-201206190-00004].
93. Wolk A, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21 [PMID: 11227921].
94. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-S103 [PMID: 15508109 DOI: 10.1053/j.gastro.2004.09.021].
95. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218-224 [PMID: 15664247 DOI: 10.1016/j.jhep.2004.10.005].
96. World Health Organization. Global status report on non-communicable diseases 2010. [Accessed 2011 April]. Available from: URL: http://www.who.int/nmh/publications/ncd_report_full_en.pdf.
97. Ramachandran A, Snehalatha C. Rising burden of obesity in Asia. J Obes 2010; 2010: pii: 868573 [PMID: 20871654 DOI: 10.1155/2010/868573].
98. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688 [PMID: 17098087 DOI: 10.1016/s0140-673 6(06)69703-1].
99. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussles, Belgium: International Diabetes Federation, 2013.
100. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468 [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065].
101. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380 [PMID: 16527702 DOI: 10.1016/j.cgh.2005.12.007].
102. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219 [PMID: 12717402 DOI: 10.1053/jhep.2003.50193].
103. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391 [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027].
104. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832 [PMID: 20432259 DOI: 10.1002/hep.23594].
105. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443 [PMID: 21128245 DOI: 10.1002/ijc.25797].
106. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-457 [PMID: 18627003 DOI: 10.1002/hep.22350].
107. Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, Yokomori H, Inagaki Y. Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). Cancers (Basel) 2014; 6: 1220-1255 [PMID: 24978432 DOI: 10.3390/cancers6031220].
108. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010; 25: 657-663 [PMID: 20492323 DOI: 10.1111/j. 1440-1746.2 009.06167.x].
109. Fazeli Z, Pourhoseingholi MA, Vahedi M, Zali MR. Burden of Hepatocellular Carcinoma in Aisa. Asian Pacific J Cancer Prevention 2012; 13: 5955-5958 [DOI: 10.7314/APJCP.2012.13.12.5955].
110. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273 [PMID: 18848855 DOI: 10.1016/j. vaccine.2008.09.056].
111. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25: 19-25 [PMID: 20136972 DOI: 10.1111/j.1440-1746.2009.06165.x].
112. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol 2009; 24: 1352-1357 [PMID: 19702903 DOI: 10.1111/j.1440-1746.2009.05985.x].
113. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364].
114. Ashtari S, Vahedi M, Pourhoseingholi MA, Karkhane M, Kimiia Z, Pourhoseingholi A, Safaee A, Moghimi-Dehkordi B, Zali MR, Alavian SM. Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon 2013; 13: e8415 [PMID: 23930132 DOI: 10.5812/hepatmon.8415].
115. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon a-2a and a-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis 2012; 12: 357 [PMID: 23245594 DOI: 10.1186/1471-23 34-12-357].
116. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199 [PMID: 19879972 DOI: 10.1016/j.cgh.2009.10.026].
117. Ashtari S, Vahedi M, Pourhoseingholi MA, Pourhoseingholi A, Safaee A, Moghimi-Dehkordi B, Zali MR. Estimation of average diagnosis and treatment costs of hepatitis C. Gastroenterol Hepatol Bed Bench 2012; 5: 139-145 [PMID: 24834215].
118. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150: 1051-1054 [PMID: 2158773 DOI: 10.1001/archinte. 15 0.5.1051].
119. World Health Organization. Global Immunization Data. [Accessed 2012 March]. Available from: URL: http://www.who.int/immunization/monitoring_surveillance/global_immunization_data.pdf.
120. World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. [Accessed 2012]. Available from: URL: http://www.who.int/csr/disease/hepatitis/GHP_Framework_En.pdf.
121. McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-633 [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x].
122. Farrell GC. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 607-610 [PMID: 17444844 DOI: 10.1111/j. 1440-1746.2 007.04969.x].
123. Li L, Fan HB, Yang DL. [An introduction of the consensus statements on the diagnosis, management and treatment of hepatitis C virus infection from the Asian Pacific Association for the Study of the Liver]. Zhonghua Gan Zang Bing Za Zhi 2007; 15: 955-957 [PMID: 18171543].
124. Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a sevenyear prospective follow-up. J Hepatol 2012; 56: 1145-1151 [PMID: 22245895 DOI: 10.1016/j.jhep.2011.12.011].
125. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758 [PMID: 20331505 DOI: 10.1111/j.1478-3231.2010.02223.x].
126. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96: 2601-2608 [PMID: 21752887 DOI: 10.1210/jc.2010-2415].
127. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-1946 [PMID: 20166205 DOI: 10.1002/cncr.24982].